Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2015 | REMoDL-B clinical trial: results presented at ASH 2015

Andrew Davies • 4 Dec 2015
ASH 2015
B-Cell Lymphoma Bortezomib

Andrew Davies, MD, BSc, MRCP, PhD, from the University of Southampton, Southampton, UK provides an overview of the REMoDL-B clinical trial, a Phase III study for untreated diffuse large B-cell lymphoma patients. The aims of this study were to compare R-CHOP plus bortezomib to R-CHOP alone, as front-line therapy. The trial also aimed to develop a gene expression profiling test to determine the genetic sub-type (ABC or GCB), and if the different sub-types would have an increased benefit from the addition of bortezomib therapy.

More from Andrew Davies

Novel therapies in NHL: antibody-drug conjugates
Andrew Davies et al. • 17 Oct 2023
1:11
Economic burden of CAR-T therapy from a UK perspective
Andrew Davies • 24 Apr 2023
2:40
Primary analysis of the Phase III TRANSFORM study: liso-cel in second-line LBCL
Andrew Davies • 24 Apr 2023
1:44
REMoDL-B: bortezomib + R-CHOP versus R-CHOP in patients with DLBCL
Andrew Davies • 24 Apr 2023

Related Videos

1:13
Antibody-drug conjugates for the treatment of lymphoma
Pau Abrisqueta • 5 Apr 2024
3:18
A Phase I study of JBH492, an anti-CCR7 antibody-drug conjugate, in lymphoid malignancies
Pau Abrisqueta • 5 Apr 2024
4:09
Real-world safety and efficacy of liso-cel in R/R large B-cell lymphoma
Jennifer Crombie • 9 Dec 2023
2:06
Odronextamab in CAR-T relapsed diffuse large B-cell lymphoma
Jennifer Crombie • 9 Dec 2023
The content of VJHemOnc is intended for healthcare professionals